D Milligan

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

David C. Linch, A. H. Goldstone, Annabel McMillan et al. · The Lancet · 1993 · 1K citations

Transplantation, Marrow Transplantation, Stem Cell Transplantation +9

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

Peter Dreger, Paolo Corradini, Eva Kimby et al. · Leukemia · 2006 · 381 citations

Cell Therapy, Transplantation, Marrow Transplantation +9

Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen

J. M. Davies, Rosemary A. Barnes, D Milligan · Clinical Medicine · 2002 · 284 citations · Full text

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

Peter Dreger, R. Brand, D Milligan et al. · Leukemia · 2005 · 159 citations

Cell Therapy, Oncology, Marrow Transplantation +10

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Alan K. Burnett, Robert K. Hills, Ann E. Hunter et al. · Leukemia · 2012 · 158 citations · Full text

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +9